NEVPF Stock - Abliva AB (publ)
Unlock GoAI Insights for NEVPF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $137,000 | $31,000 | $151,000 | $216,000 | $134,000 |
| Gross Profit | $-68,682,000 | $-84,905,000 | $-32,358,000 | $-32,209,000 | $-31,458,000 |
| Gross Margin | -50132.8% | -273887.1% | -21429.1% | -14911.6% | -23476.1% |
| Operating Income | $-96,548,000 | $-83,190,000 | $-123,482,000 | $-60,071,000 | $-77,075,000 |
| Net Income | $-95,509,000 | $-84,964,000 | $-123,498,000 | $-59,883,000 | $-76,874,000 |
| Net Margin | -69714.6% | -274077.4% | -81786.8% | -27723.6% | -57368.7% |
| EPS | $-0.09 | $-0.11 | $-0.33 | $-0.23 | $-0.44 |
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Visit WebsiteEarnings History & Surprises
NEVPFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 20, 2025 | — | — | — | — |
Q2 2025 | May 22, 2025 | — | — | — | — |
Q1 2025 | Feb 21, 2025 | — | $-0.02 | — | — |
Q4 2024 | Nov 29, 2024 | — | $-0.02 | — | — |
Q3 2024 | Aug 22, 2024 | — | $-0.02 | — | — |
Q2 2024 | May 23, 2024 | — | $-0.02 | — | — |
Q1 2024 | Feb 23, 2024 | — | $-0.02 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.03 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.02 | — | — |
Q2 2023 | May 23, 2023 | — | $-0.02 | — | — |
Q1 2023 | Feb 24, 2023 | — | $-0.02 | — | — |
Q4 2022 | Nov 22, 2022 | — | $-0.04 | — | — |
Q3 2022 | Aug 19, 2022 | — | $-0.05 | — | — |
Q2 2022 | May 31, 2022 | — | $-0.01 | — | — |
Q1 2022 | Feb 22, 2022 | — | $-0.01 | — | — |
Q4 2021 | Nov 19, 2021 | — | $-0.01 | — | — |
Q3 2021 | Aug 19, 2021 | — | $-0.01 | — | — |
Q2 2021 | May 20, 2021 | — | $-0.01 | — | — |
Q1 2021 | Feb 19, 2021 | — | $-0.04 | — | — |
Q4 2020 | Nov 20, 2020 | — | $-0.03 | — | — |
Latest News
Frequently Asked Questions about NEVPF
What is NEVPF's current stock price?
What is the analyst price target for NEVPF?
What sector is Abliva AB (publ) in?
What is NEVPF's market cap?
Does NEVPF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NEVPF for comparison